Category Archives: ARTAS

Restoration Robotics (“HAIR”) IPO

Restoration Robotics is a privately held company that manufactures the world leading ARTAS robotic hair transplantation system that I have discussed on this blog several times in the past (search via the “Categories” menu). This robot has revolutionized follicular unit extraction from the back of patient scalps during an FUE hair transplantation procedure. In future, ARTAS may also become an expert at hair placement in the front and crown of patient scalps.

I just found out that Restoration Robotics will undertake an initial public offering (IPO) on the NASDAQ stock exchange tomorrow October 12th, 2017. The company’s stock ticker will be “HAIR”, which was surprisingly not already taken. They aim to price shares at between $7 and $9 and will issue 3.1 million of them. Restoration Robotics had $20 million in revenue last year, but was not yet profitable it seems.

I have done limited basic stock trading in my life, but will be keen to follow this IPO tomorrow even though I do not intend to buy. I do want to learn how an IPO works at the get go and, if awake, follow real-time trends. For any financial experts who care to comment:

  • How easy is it for the common man to purchase stocks during an IPO? Any website recommendations?
  • Will “HAIR” start trading as soon as the NASDAQ market opens at 9:30 am or will it be later in the day?
  • Did Restoration Robotics have to make public significant financial details regarding its past few years of operations/performance before being allowed to proceed with the IPO?

ARTAS Twitter Account.

Brief Items of Interest, July 2015

Hair loss news first:

Histogen filed form D for equity financing and raised about $10 million in funding.  The filing took place on June 29th, but I read about it in a new July Bald Truth hair loss forum thread. Nothing too interesting or impressive other than the company name and its significance to us in the hair loss world. Glad to read that Histogen is still kicking.  The octafinance website states that biotech companies usually sell around three-quarters of their offering, but Histogen managed to sell 100 percent of its offering, which may be a sign of investor trust and confidence.

— An interesting study (on humans and not mice) from Japan about the increase in sebaceous gland area (but not size) in patients suffering from androgenic alopecia.

— I discussed Dr. Carlos Wesley and his  revolutionary PiloFocus  scarless hair transplant surgery last year after he was profiled in an excellent article in the Verge magazine.  Dr. Wesley has now managed to get detailed coverage in the prestigious BBC website’s future section.  Great article yet again.

More favorable feedback on ARTAS, including a video.  Dr. Thomas Griffin seems like a sincere doctor.  I like his description of the newly added PRP at his practice: “what we’re trying to do is maximize our results for our patients.”  Some doctors will delude patients into thinking that PRP means guaranteed hair growth.

And now on to medical items of interest:

— Fascinating article on CRISPR DNA editing.

— Some hair loss sufferers who take Finasteride complain about getting gynecomastia (man boobs) as a side effect.  Usually, this side effect is transient or minimal, but in some rare cases, it can be quite bad and lead to major growth in breast size.  Several weeks ago, Reddit user Wulfgar1  started an ask me anything (AMA) about his gynecomastia surgery.  He included quite impressive before and after photos, and answered almost all of the 100s of questions that were asked of him.  Note that Wulfgar1 had gynecomastia since the age of 12, so his man boobs were not due to taking Finasteride.

— A Chinese girl suffering from hypertrichosis (an extreme level of excessive body hair) is raising funds for laser hair removal. A bit unusual that the least hairy race on earth has such cases.  Also see the ending to my post from last year on whether Asians are more evolved than other races.

— A good summary of 30 futuristic breakthroughs that happened during the first half of 2015.  I like the heavy focus on medical breakthroughs rather than on less interesting breakthroughs that will just give us better, faster, cheaper or newer “stuff”.

Theranos’ fingerprick blood test gets FDA approval.  This company is likely to revolutionize blood testing in the coming years. Also this month, the company obtained FDA approval that will lead to at-home testing.   The company’s CEO Elizabeth Holmes is the youngest female billionaire in the US.  Theranos is a very secretive privately-held company, and its Board of Directors is filled with retired government officials, including major ones such as Henry Kissinger and William Perry.  I wonder if companies that are working on a hair loss cure should try to get politicians on board and if that can helps garner faster FDA approval?

— Non-medical, but nevertheless worth a mention:  3D printed house in China assembled in 3 hours.  And it looks decent!